about
Oligonucleotide therapeutic approaches for Huntington diseaseHuntingtin promotes cell survival by preventing Pak2 cleavageIron dysregulation in Huntington's diseaseMutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathwayHuntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study.Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.IKKalpha and IKKbeta regulation of DNA damage-induced cleavage of huntingtin.Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.Therapeutic approaches to preventing cell death in Huntington diseaseAntisense therapy in neurologyFunctions of huntingtin in germ layer specification and organogenesis.Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.Huntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy.Allele-specific silencing of mutant Huntington's disease gene.Mitochondria as a therapeutic target for aging and neurodegenerative diseases.Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo.Autophagy and neuronal cell death in neurological disordersAn Intrabody Drug (rAAV6-INT41) Reduces the Binding of N-Terminal Huntingtin Fragment(s) to DNA to Basal Levels in PC12 Cells and Delays Cognitive Loss in the R6/2 Animal ModelRational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.Mitochondrial structural and functional dynamics in Huntington's disease.Molecular mechanisms and potential therapeutical targets in Huntington's disease.The role of IκB kinase complex in the neurobiology of Huntington's disease.The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathologyProtein truncation as a common denominator of human neurodegenerative foldopathies.More alive than dead: non-apoptotic roles for caspases in neuronal development, plasticity and disease.Regulation of RE1 protein silencing transcription factor (REST) expression by HIP1 protein interactor (HIPPI).Huntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells.Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD.Sp1 regulates human huntingtin gene expression.Mutant HFE H63D protein is associated with prolonged endoplasmic reticulum stress and increased neuronal vulnerability.Nuclear Compartmentalization of Serine Racemase Regulates D-Serine Production: IMPLICATIONS FOR N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ACTIVATION.Cardiac Fas-Dependent and Mitochondria-Dependent Apoptotic Pathways in a Transgenic Mouse Model of Huntington's Disease.An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin.Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release.Evaluating the current state of the art of Huntington disease research: a scientometric analysis.
P2860
Q22306293-5D638CA5-B664-4F0A-BA4B-61502ED6E056Q24314724-C0F0BDD7-974E-4BF2-A5E8-EDAF2DF0FA56Q26829932-43A86AD1-9C06-4137-AD6F-BC2BC27407C2Q28576523-2205304E-320B-4948-9652-CEC06DC8FA2CQ30438950-20BA92DD-809B-49A2-8D2E-79E52F2741CEQ33265508-9C46D13B-C341-4A52-AC27-7F23FAD69313Q33458331-36A71651-1C78-4EFF-9750-C5D3ECE11647Q33831774-2786BF9A-0A7F-4DC9-AE09-6BC25811EE33Q34221351-FD3E8AF7-443C-4EB1-B372-C8FED373CB9EQ34411338-AF39B1E4-03AF-4481-84EE-453A9C522D11Q34608717-BAC8961F-FFF8-4196-9120-C42FD4E92C7AQ34965525-A7F032C1-7ED0-4E40-A43B-1C95D50F8FEBQ35072356-DF34E7BD-51CA-4D2B-80A2-A232677E2971Q35158643-023EF613-366D-4589-A9F2-50D0FBE368D1Q35194425-44239AEE-5220-4976-A485-8470DC8AADBFQ35807409-71F6DA64-895E-4CFC-AD11-8576C389B9EDQ35905407-FE8FD099-5CD0-4144-83CF-3AC0A9DB7E40Q36329444-DFA983B3-18CD-40F7-BF47-D8F402E1EDF2Q37198517-D29401B1-7624-4E69-953B-3DDB0167DC93Q37327574-8F0058DB-7318-47D4-AC78-4592DEDA2FB4Q37356257-C3867846-EB55-41C1-B323-917FC75111FFQ37776087-83120942-620D-47C4-A492-3CCEA3E5E7AAQ37873608-4153F04A-8ED0-4947-9B65-B9995C9964B4Q37969749-9A49B7B5-FABA-4B14-83DC-2C9DD13C02F3Q38091670-6DC6AD91-916D-4E79-89F3-2EF335394C29Q38667534-E055FD59-F822-4A03-A911-62675B9DC985Q38674322-16666F52-949D-4B74-8CED-DC18C64BD8C1Q38790183-547D2AC1-765B-4F86-8290-D0C83976FA74Q38791517-CFAE2A5F-203C-4A90-B5CA-B791B2939F46Q39383676-87EB2194-C20B-42AB-A95F-D33C62A3D1ADQ39586425-D13CA2AB-A02E-475A-A336-C23176293002Q42183920-35F04C76-A947-4890-BA80-97FA33BC5E0AQ45304916-6BE19A73-2BA9-4A4C-8390-CE1268D3507BQ47073933-099B2E14-131E-4D13-BF35-271A0166550AQ47851900-4548BC40-9862-4A27-A436-3C9185BCC359Q50015412-D23DA20B-A930-42EF-96C5-8C4F1057CF01
P2860
description
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im November 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/12/13)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/12/13)
@nl
наукова стаття, опублікована в грудні 2006
@uk
مقالة علمية (نشرت في 13-12-2006)
@ar
name
Huntingtin inhibits caspase-3 activation
@ast
Huntingtin inhibits caspase-3 activation
@en
Huntingtin inhibits caspase-3 activation
@nl
type
label
Huntingtin inhibits caspase-3 activation
@ast
Huntingtin inhibits caspase-3 activation
@en
Huntingtin inhibits caspase-3 activation
@nl
prefLabel
Huntingtin inhibits caspase-3 activation
@ast
Huntingtin inhibits caspase-3 activation
@en
Huntingtin inhibits caspase-3 activation
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Huntingtin inhibits caspase-3 activation
@en
P2093
Ioannis Dragatsis
Jeremy M van Raamsdonk
Robert M Friedlander
P2860
P304
P3181
P356
10.1038/SJ.EMBOJ.7601445
P407
P577
2006-11-23T00:00:00Z